medmix appoints Itee Satpathy as Chief Human Resources Officer

19 November 2021

Ad hoc announcement pursuant to Art. 53 LR

medmix announced today that Itee Satpathy is to succeed Friedrich von Gadow as Chief Human Resources Officer and member of the Executive Committee, effective December 1, 2021. Friedrich von Gadow is returning to Sulzer as he has been appointed as Head Human Resources for Switzerland.

Itee has been serving for the last three years as Sulzer’s Global Head of People Development and Internal Communications, prior to which she was globally responsible for Talent Development and Diversity at Syngenta. Previously, she has worked across various areas of the HR function at Novartis. Itee Satpathy holds a Bachelors’ degree in Economics and Statistics from Utkal University, India, and a Master’s specialization in Human Resources from XLRI Jamshedpur.

“Itee brings a wealth of experience in talent management, business partnering, engagement, communications and sustainability with a proven ability to lead a global HR function. She will play a key role in medmix’ upcoming phase of sustainable growth, as well as creating in a diverse and passionate global team,” said CEO Girts Cimermans. “We wish Itee every success in her new role and thank Friedrich for his commitment to medmix, wishing him the best for his endeavors at Sulzer.”

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 12 production sites worldwide together with our highly motivated and experienced team of 1’900 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX).

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.